Evidence map›Paper›PMID 25470014›Full record

ReviewCurrent opinion in nephrology and hypertension2015

Obesity and kidney disease: differential effects of obesity on adipose tissue and kidney inflammation and fibrosis.

Anne-Emilie Declèves, Kumar Sharma

Open access · greenAbstract readReview
In one paragraph

Review in Current opinion in nephrology and hypertension, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed, 1 pooled it
8.6field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 1 synthesis or guideline pooled it, 88 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Obesity-Related Glomerulosclerosis-How Adiposity Damages the Kidneys.International journal of molecular sciences · 2025
    Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Observational
  15. Review
  16. Review
  17. Article
  18. Kidney Damage Caused by Obesity and Its Feasible Treatment Drugs.International journal of molecular sciences · 2022
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 2 countries.

Anne-Emilie DeclèvesaCenter for Renal Translational Medicine, La Jolla, California, USA bLaboratory of Experimental Nephrology, Faculty of Medicine, Université Libre de Bruxelles (ULB), Brussels, Belgium cInstitute for Metabolomic Medicine, University of California San Diego, Veterans Affairs San Diego Healthcare System, La Jolla, California, USA.
Kumar Sharma
Université Libre de Bruxelles · BEVA San Diego Healthcare System · US

Funding

Novel Paradigms in Diabetic ComplicationsDP3DK094352 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SHARMA, KUMAR · 2011 to 2011
$6.0M
Adiponectin and PodocytesI01BX000277 · VA · VA SAN DIEGO HEALTHCARE SYSTEM · PI SHARMA, KUMAR · 2009 to 2013
–
BLRD VA I01 BX000277NIDDK NIH HHS DP3 DK094352NIDDK NIH HHS DP3DK094352
6 · The paper itself

Abstract

purpose of reviewTo provide a perspective by investigating the potential cross-talk between the adipose tissue and the kidney during obesity. RECENT

findingsIt is well established that excessive caloric intake contributes to organ injury. The associated increased adiposity initiates a cascade of cellular events that leads to progressive obesity-associated diseases such as kidney disease. Recent evidence has indicated that adipose tissue produces bioactive substances that contribute to obesity-related kidney disease, altering the renal function and structure. In parallel, proinflammatory processes within the adipose tissue can also lead to pathophysiological changes in the kidney during the obese state. SUMMARY: Despite considerable efforts to better characterize the pathophysiology of obesity-related metabolic disease, there are still a lack of efficient therapeutic strategies. New strategies focused on regulating adipose function with respect to AMP-activated protein kinase activation, NADPH oxidase function, and TGF-β may contribute to reducing adipose inflammation that may also provide renoprotection.

Indexed as

Adipose TissueAMP-Activated Protein KinasesCytokinesFibrosisHumansHypoxia-Inducible Factor 1, alpha SubunitInflammationInsulin ResistanceKidneyNADPH OxidasesNephritisObesityReceptors, G-Protein-CoupledTransforming Growth Factor betaAMP-Activated Protein KinasesCytokinesHIF1A protein, humanHypoxia-Inducible Factor 1, alpha SubunitNADPH OxidasesReceptors, G-Protein-CoupledTransforming Growth Factor beta

Identifiers

PMID25470014
PMCPMC4847436
OpenAlexW2038974136

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.